Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.
Difloxacin (A-56619) and A-56620, two novel fluoroquinolones, were tested in comparison with ciprofloxacin, cefoxitin, and combined clindamycin and gentamicin in the treatment of experimentally induced intraabdominal abscess associated with Bacteroides fragilis. Difloxacin was found to be as effective as clindamycin-gentamicin. A-56620, despite achieving subtherapeutic levels in serum, was found to be as effective as cefoxitin. Both difloxacin and A-56620 were effective in vivo against experimentally induced intra-abdominal abscess in rats.
D000038:Abscess / Q000188:drug therapy; D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D001202:Ascitic Fluid / Q000378:metabolism; D001442:Bacteroides Infections / Q000188:drug therapy*; D001441:Bacteroides fragilis / Q000187:drug effects; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D004926:Escherichia coli / Q000378:metabolism; D024841:Fluoroquinolones; D006207:Half-Life; D008297:Male; D008826:Microbial Sensitivity Tests; D051381:Rats; D011919:Rats, Inbred Strains
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D002939:Ciprofloxacin; C047225:difloxacin; C047224:sarafloxacin